Non-Tuberculous Mycobacterial Pulmonary Disease Prevalence Status in China

Chunfa Liu,Yimeng Song,Wencong He,Dongxin Liu,Ping He,Jingjing Bao,Xinyang Wang,Xichao Ou,Bing Zhao,Jiale Fan,Qian Cheng,Yang Zhou,Yuanyuan Song,Yang Zheng,Hui Xia,Shengfen Wang,Yanming Li,Yanlin Zhao
DOI: https://doi.org/10.21203/rs.3.rs-47871/v1
2020-07-30
Abstract:Abstract Introduction: The information on the pulmonary disease caused by non-tuberculosis mycobacterium (NTM) in China is limited, mainly based on local or regional studies. Methods: Retrospective study involving 72 tuberculosis clusters provided sputa of enrolled presumptive cases for mycobacterial and drug-susceptibility testing in 31 provinces of Chinese mainland. Minimal inhibitory concentrations (MICs) test was used to measure the susceptibility of NTM isolates. Results: Of 4917 mycobacterial isolates cultured, 317 (6.4%, 95% confidence interval [CI], 5.8 to 7.2) isolates were confirmed as NTM, among 207 (12.1%, 95% CI, 10.6 to 13.8) isolates were detected from the southeastern region with the highest NTM prevalence. Slow growing mycobacteria (SGM) contributed 93.3% (95% CI, 76.4 to 98.8) and 56.1% (95% CI, 50.1 to 61.9) in northern and southern China, respectively. A total of 29 species were detected, the three most frequently isolated NTM belonged to Mycobacterium abscessus complex (36.0%, 95% CI, 33.3 to 38.7), Mycobacterium avium-intracellulare complex (34.1%, 95% CI, 29.1 to 39.5), Mycobacterium kansasii (9.8%, 95% CI, 8.1 to 11.4), respectively. Clarithromycin and amikacin were showed lower resistant rates to NTM in vitro. Conclusions: The southeastern region should be paid more attention to NTM pulmonary disease. More rapid growing mycobacteria (RGM) were present in southern China than the northern (P < 0.001). Considering clear correlations between in vitro activity and the in vivo outcomes of treatment, macrolides and amikacin were recommended in NTM treatment in China.
What problem does this paper attempt to address?